244 related articles for article (PubMed ID: 31264435)
1. Lung Cancer Genomics.
Parikh AR
Acta Med Acad; 2019 Apr; 48(1):78-83. PubMed ID: 31264435
[TBL] [Abstract][Full Text] [Related]
2. Genomic Testing in Lung Cancer: Past, Present, and Future.
Mascaux C; Tsao MS; Hirsch FR
J Natl Compr Canc Netw; 2018 Mar; 16(3):323-334. PubMed ID: 29523671
[TBL] [Abstract][Full Text] [Related]
3. Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities.
Gutierrez ME; Choi K; Lanman RB; Licitra EJ; Skrzypczak SM; Pe Benito R; Wu T; Arunajadai S; Kaur S; Harper H; Pecora AL; Schultz EV; Goldberg SL
Clin Lung Cancer; 2017 Nov; 18(6):651-659. PubMed ID: 28479369
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and possible applications of genomics in lung cancer.
Alharbi KK
Asian Pac J Cancer Prev; 2015; 16(5):1693-8. PubMed ID: 25773789
[TBL] [Abstract][Full Text] [Related]
5. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
[TBL] [Abstract][Full Text] [Related]
6. Genomics-Enabled Precision Medicine for Cancer.
Roos A; Byron SA
Cancer Treat Res; 2019; 178():137-169. PubMed ID: 31209844
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in lung cancer genomics: Application in targeted therapy.
Pathak N; Chitikela S; Malik PS
Adv Genet; 2021; 108():201-275. PubMed ID: 34844713
[TBL] [Abstract][Full Text] [Related]
8. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
9. Getting personal: Head and neck cancer management in the era of genomic medicine.
Birkeland AC; Uhlmann WR; Brenner JC; Shuman AG
Head Neck; 2016 Apr; 38 Suppl 1(Suppl 1):E2250-8. PubMed ID: 25995036
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.
Vigneswaran J; Tan YH; Murgu SD; Won BM; Patton KA; Villaflor VM; Hoffman PC; Hensing T; Hogarth DK; Malik R; MacMahon H; Mueller J; Simon CA; Vigneswaran WT; Wigfield CH; Ferguson MK; Husain AN; Vokes EE; Salgia R
Oncotarget; 2016 Apr; 7(14):18876-86. PubMed ID: 26934441
[TBL] [Abstract][Full Text] [Related]
11. [THE IMPACT OF MOLECULAR PROFILING USING NEXT-GENERATION SEQUENCING IN ADVANCED LUNG CANCER].
Belilovski Rozenblum A; Ilouze M; Dudnik E; Soussan-Gutman L; Dvir A; Peled N
Harefuah; 2017 Nov; 156(11):686-691. PubMed ID: 29198084
[TBL] [Abstract][Full Text] [Related]
12. LungCARD - Report on worldwide research and clinical practices related to lung cancer.
Jankovic R; J Goncalves H; Cavic M; Clemente C; Lind M; Murillo Carrasco A; Nadifi S; Khyatti M; Adebambo T; Egamberdiev D
J BUON; 2019; 24(1):11-19. PubMed ID: 30941946
[TBL] [Abstract][Full Text] [Related]
13. The possibility of clinical sequencing in the management of cancer.
Kou T; Kanai M; Matsumoto S; Okuno Y; Muto M
Jpn J Clin Oncol; 2016 May; 46(5):399-406. PubMed ID: 26917600
[TBL] [Abstract][Full Text] [Related]
14. Precision Oncology: Who, How, What, When, and When Not?
Schwartzberg L; Kim ES; Liu D; Schrag D
Am Soc Clin Oncol Educ Book; 2017; 37():160-169. PubMed ID: 28561651
[TBL] [Abstract][Full Text] [Related]
15. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
Schrock AB; Li SD; Frampton GM; Suh J; Braun E; Mehra R; Buck SC; Bufill JA; Peled N; Karim NA; Hsieh KC; Doria M; Knost J; Chen R; Ou SI; Ross JS; Stephens PJ; Fishkin P; Miller VA; Ali SM; Halmos B; Liu JJ
J Thorac Oncol; 2017 Jun; 12(6):932-942. PubMed ID: 28315738
[TBL] [Abstract][Full Text] [Related]
17. Genomic medicine and risk prediction across the disease spectrum.
Kotze MJ; Lückhoff HK; Peeters AV; Baatjes K; Schoeman M; van der Merwe L; Grant KA; Fisher LR; van der Merwe N; Pretorius J; van Velden DP; Myburgh EJ; Pienaar FM; van Rensburg SJ; Yako YY; September AV; Moremi KE; Cronje FJ; Tiffin N; Bouwens CS; Bezuidenhout J; Apffelstaedt JP; Hough FS; Erasmus RT; Schneider JW
Crit Rev Clin Lab Sci; 2015; 52(3):120-37. PubMed ID: 25597499
[TBL] [Abstract][Full Text] [Related]
18. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
[TBL] [Abstract][Full Text] [Related]
19. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
Pécuchet N; Legras A; Laurent-Puig P; Blons H
Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
[TBL] [Abstract][Full Text] [Related]
20. Broad Genomic Testing in NSCLC: No Survival Benefit?
Cancer Discov; 2018 Oct; 8(10):1201. PubMed ID: 30171013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]